Brown JE - Search Results

1

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.

Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S. Lipton A, et al. Among authors: brown je. Eur J Cancer. 2012 Nov;48(16):3082-92. doi: 10.1016/j.ejca.2012.08.002. Epub 2012 Sep 10. Eur J Cancer. 2012. PMID: 22975218

2

Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.

Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE. Brown JE, et al. J Natl Cancer Inst. 2005 Jan 5;97(1):59-69. doi: 10.1093/jnci/dji002. J Natl Cancer Inst. 2005. PMID: 15632381

3

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.

Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Zheng M, Hei YJ, Seaman J, Cook R. Coleman RE, et al. Among authors: brown je. J Clin Oncol. 2005 Aug 1;23(22):4925-35. doi: 10.1200/JCO.2005.06.091. Epub 2005 Jun 27. J Clin Oncol. 2005. PMID: 15983391

4

Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer.

Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F, Smith MR. Cook RJ, et al. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3361-7. doi: 10.1158/1078-0432.CCR-06-0269. Clin Cancer Res. 2006. PMID: 16740758 Clinical Trial.

5

Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer.

Smith MR, Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F. Smith MR, et al. Urology. 2007 Aug;70(2):315-9. doi: 10.1016/j.urology.2007.03.071. Urology. 2007. PMID: 17826496 Free PMC article. Clinical Trial.

6

Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.

Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR, Brown JE, Coleman RE. Hirsh V, et al. Among authors: brown je. J Thorac Oncol. 2008 Mar;3(3):228-36. doi: 10.1097/JTO.0b013e3181651c0e. J Thorac Oncol. 2008. PMID: 18317064 Free article. Clinical Trial.

7

Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.

Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, Brown JE, Coleman RE. Lipton A, et al. Among authors: brown je. Cancer. 2008 Jul 1;113(1):193-201. doi: 10.1002/cncr.23529. Cancer. 2008. PMID: 18459173 Free article.

8

Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions.

Coleman R, Brown J, Terpos E, Lipton A, Smith MR, Cook R, Major P. Coleman R, et al. Cancer Treat Rev. 2008 Nov;34(7):629-39. doi: 10.1016/j.ctrv.2008.05.001. Epub 2008 Jun 24. Cancer Treat Rev. 2008. PMID: 18579314 Free PMC article. Review.

9

Prognostic factors for skeletal complications from metastatic bone disease in breast cancer.

Brown JE, Cook RJ, Lipton A, Costa L, Coleman RE. Brown JE, et al. Breast Cancer Res Treat. 2010 Oct;123(3):767-79. doi: 10.1007/s10549-010-0981-1. Epub 2010 Jun 24. Breast Cancer Res Treat. 2010. PMID: 20574672

10

Zoledronic acid.

Coleman R, Burkinshaw R, Winter M, Neville-Webbe H, Lester J, Woodward E, Brown J. Coleman R, et al. Expert Opin Drug Saf. 2011 Jan;10(1):133-45. doi: 10.1517/14740338.2011.540387. Epub 2010 Nov 29. Expert Opin Drug Saf. 2011. PMID: 21114419 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

754 results

Search Page